Mirum Pharmaceuticals Inc (NAS:MIRM)
$ 42.28 0.67 (1.61%) Market Cap: 2.02 Bil Enterprise Value: 2.02 Bil PE Ratio: 0 PB Ratio: 8.78 GF Score: 51/100

Mirum Pharmaceuticals Inc To Acquire Travere Therapeutics Inc Call Transcript

Jul 17, 2023 / 12:30PM GMT
Release Date Price: $27.14 (+3.39%)
Operator

Hello, and welcome to the Mirum Pharmaceuticals' business update. My name is [Elliot], and I will be coordinating your call today. (Operator Instructions) I'd now like to hand over to Andrew McKibben, Vice President of Investor Relations. The floor is yours. Please go ahead.

Andrew McKibben
Mirum Pharmaceuticals, Inc. - VP of IR and Finance

Thanks, [Elliot], and good morning, everyone. I'd like to welcome you to Mirum Pharmaceuticals conference call. I'm joined today by our President and CEO, Chris Peetz; our Chief Operating Officer, Peter Radovich; and our Head of R&D, Pam Vig. For our Q&A session, we are also joined by our Chief Development Officer, Lara Longpre.

Earlier today, Mirum issued a news release announcing its acquisition of Travere Therapeutics product portfolio of bile acid therapeutics for rare genetic pediatric diseases. This news release can be found in the Investors section of our website. Speakers will be referencing a transaction announcement presentation that can be found in the Events section of our website.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot